(UroToday.com) Many new therapies have become available for men with metastatic castration resistant prostate cancer (mCRPC) since 2004. However, real-world data regarding how patients do on these therapies is lacking. In this poster, Dr. Caram and colleagues utilize the Veterans Health Affairs Corporate Data Warehouse to identify 4,998 veterans with mCRPC who received first-line therapy between 2010 and 2017. Overall survival by treatment was calculated and then adjusted for various patient and disease factors (starting PSA level, prognostic group).
As shown in the graph below, overall survival improved between 2010 and 2017, with fewer men receiving ketoconazole at the end of this period and more patients receiving novel androgen pathway inhibitors.
However, when adjusted for prognostic labs (hemoglobin, alkaline phosphatase and albumin) as well as starting PSA, year of treatment had no significant association with overall survival. Indeed, the percentage of patients with abnormal prognostic labs dropped by 2017, as did starting PSA. This suggests that improvements in mCRPC survival may be related to the lead time bias of treating patients earlier in their mCRPC disease course.
Presented by: Megan E.V. Caram, MD, Clinical Assistant Professor and Medical Oncologist at the Rogel Cancer Center, University of Michigan, Ann Arbor, MI
Written by: Alok K. Tewari, MD, PhD, medical oncologist at Dana-Farber Cancer Institute, @aloktewar on Twitter during the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, Thursday Feb 17 – Saturday Feb 19, 2022